πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 7566714

Methods and compositions for the treatment of metabolic disorders

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Jul 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7563446

Methods and compositions for inducing autoimmunity in the treatment of cancers

The Board of Regents of the University of Texas System Β· Granted Tue Jul 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7557081

Alpha-1-acid glycoprotein for the treatment of diabetes

Essential Skincare, LLC Β· Granted Tue Jul 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7550617

Compositions and methods for the treatment of renal and cardiovascular disease

The Board of Regents of the University of Texas System Β· Granted Tue Jun 23 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 18 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7550454

Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of tr

ACADIA Pharmaceuticals Inc. Β· Granted Tue Jun 23 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 18 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7544358

Treatment of acute lung injury, fibrosis and metastasis with antagonists of Ξ±vΞ²6

The Regents of the University of California Β· Granted Tue Jun 09 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 04 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7541331

Surfactant treatment regimen

Discovery Laboratories, Inc. Β· Granted Tue Jun 02 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7541040

Chimeric molecule for the treatment of th2-like cytokine mediated disorders

The United States of America as represented by the Department of Health and Human Serivces Β· Granted Tue Jun 02 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7541035

Immunogenic peptides for the treatment of prostate and breast cancer

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Jun 02 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7534440

Fusion molecules and methods for treatment of immune diseases

The Regents of the University of California Β· Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7531570

Treatment of diseases using ICE inhibitors

Vertex Pharmaceuticals Incorporated Β· Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7521049

Use of VEGF inhibitors for treatment of eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7517871

Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of tr

ACADIA Pharmaceuticals Inc. Β· Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7501494

Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatme

United Biomedical, Inc. Β· Granted Tue Mar 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7501260

Methods for determining efficacy of chemotherapeutic agents for a patient prior to treatme

Precision Therapeutics, Inc. Β· Granted Tue Mar 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7491715

Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of tr

ACADIA Pharmaceuticals Inc. Β· Granted Tue Feb 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7488804

Modified fusion molecules for treatment of allergic disease

The Regents of the University of California Β· Granted Tue Feb 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7482331

Diagnosis and treatment of myocardial failure

The Regents of the University of Colorado Β· Granted Tue Jan 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7482002

Method of administering and using VEGF inhibitors for the treatment of prostate cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479275

Method of administering and using VEGF inhibitors for the treatment of colorectal cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479274

Method of administering and using VEGF inhibitors for the treatment of pancreatic carcinom

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479273

Method of administering and using VEGF inhibitors for the treatment of renal cell cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479272

Method of administering and using VEGF inhibitors for the treatment of breast cancer

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7476657

Peptides and peptidomimetics having anti-proliferative activity and/or that augment nuclei

Takeda Pharmaceutical Company Limited Β· Granted Tue Jan 13 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted